This transcript has been edited for clarity.
Dear colleagues, I am Christoph Diener, a neurologist from the University of Duisburg-Essen in Germany. This month, I'd like to highlight four new publications on stroke.
Two Studies Highlight Importance of Early Diagnosis and Treatment
In the acute treatment of stroke, there is a new way to get patients into hospitals: mobile stroke units. These are ambulances equipped with CT scanning, a small laboratory, and a stroke physician. In providing these services, the goal is to shorten the time to get the patient to thrombolysis.
A study recently published in JAMA featured data from Berlin, Germany, a city with 3.5 million inhabitants and three mobile stroke units. Investigators compared outcomes among patients with acute ischemic stroke brought to the hospital with either a mobile stroke unit or a conventional ambulance (749 vs 794 patients, respectively). The groups were well matched in terms of severity of stroke.
Investigators showed that use of a mobile stroke unit significantly improved outcome at 3 months, as measured by modified Rankin ScaleMobile stroke units reduced the time to thrombolysis by approximately 30 minutes. The rate of thrombectomy was the same between the groups, which is not surprising given that how a patient gets to the hospital is independent for this outcome. Given that mobile stroke units represent an expensive way to get patients to a hospital, it remains unknown whether this is a cost-effective approach.
COMMENTARY
4 New Stroke Studies and Guidelines to Know
Hans-Christoph Diener, MD, PhD
DisclosuresApril 16, 2021
This transcript has been edited for clarity.
Dear colleagues, I am Christoph Diener, a neurologist from the University of Duisburg-Essen in Germany. This month, I'd like to highlight four new publications on stroke.
Two Studies Highlight Importance of Early Diagnosis and Treatment
In the acute treatment of stroke, there is a new way to get patients into hospitals: mobile stroke units. These are ambulances equipped with CT scanning, a small laboratory, and a stroke physician. In providing these services, the goal is to shorten the time to get the patient to thrombolysis.
A study recently published in JAMA featured data from Berlin, Germany, a city with 3.5 million inhabitants and three mobile stroke units. Investigators compared outcomes among patients with acute ischemic stroke brought to the hospital with either a mobile stroke unit or a conventional ambulance (749 vs 794 patients, respectively). The groups were well matched in terms of severity of stroke.
Investigators showed that use of a mobile stroke unit significantly improved outcome at 3 months, as measured by modified Rankin ScaleMobile stroke units reduced the time to thrombolysis by approximately 30 minutes. The rate of thrombectomy was the same between the groups, which is not surprising given that how a patient gets to the hospital is independent for this outcome. Given that mobile stroke units represent an expensive way to get patients to a hospital, it remains unknown whether this is a cost-effective approach.
Medscape Neurology © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Hans-Christoph Diener. 4 New Stroke Studies and Guidelines to Know - Medscape - Apr 16, 2021.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Hans-Christoph Diener, MD, PhD
Professor, Department of Neurology, Stroke Center-Headache Center, University Duisburg-Essen, Essen, Germany
Disclosure: Hans-Christoph Diener, MD, PhD, has disclosed the following relevant financial relationships:
Received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from: Abbott; Addex Pharma; Alder; Allergan; Almirall; Amgen; Autonomic Technology; AstraZeneca; Bayer Vital; Berlin Chemie; Bristol-Myers Squibb; Boehringer Ingelheim; Chordate; CoAxia; Corimmun; Covidien; Coherex; CoLucid; Daiichi-Sankyo; D-Pharml Electrocore; Fresenius; GlaxoSmithKline; Grunenthal; Janssen-Cilag; Labrys Biologics Lilly; La Roche; 3M Medica; MSD; Medtronic; Menarini; MindFrame; Minster; Neuroscore; Neurobiological Technologies; Novartis; Novo-Nordisk; Johnson & Johnson; Knoll; Paion; Parke-Davis; Pierre Fabre; Pfizer Inc; Schaper and Brummer; sanofi-aventis; Schering-Plough; Servier; Solvay; Syngis; St. Jude; Talecris; Thrombogenics; WebMD Global; Weber and Weber; Wyeth; YamanouchiReceived financial support for research projects from: Allergan; Almirall; Astra/Zeneca; Bayer; Boehringer Ingelheim; Electrocore; GlaxoSmithKline; Janssen-Cilag; Lundbeck; MSD; Novartis; Pfizer; sanofi-aventis; Syngis; Talecris
Within the past year Dr Diener served as editor of Aktuelle Neurologie, Arzneimitteltherapie, Kopfschmerznews, Stroke News, and the Treatment Guidelines of the German Neurological Society; as co-editor of Cephalalgia, and on the editorial board of Lancet Neurology, Stroke, European Neurology, and Cerebrovascular Disorders.
The Department of Neurology in Essen is supported by the German Research Council (DFG), the German Ministry of Education and Research (BMBF), European Union, National Institutes of Health, Bertelsmann Foundation, and Heinz-Nixdorf Foundation.
Dr Diener has no ownership interest and does not own stocks in any pharmaceutical company.